Full-Time

Senior Security Engineer

Operational Technology

AbbVie

AbbVie

10,001+ employees

Global biopharmaceutical company developing medicines

No salary listed

Dublin, Ireland

Hybrid

Bachelor's, Master's, PhD

Category
IT & Security (1)
Required Skills
Incident Response
Cybersecurity
Vulnerability Analysis

Get referred to AbbVie

See people who can refer or advise you

Requirements
  • Demonstrated understanding of Operational Technology and Industrial Control Systems environments in pharmaceutical or similar regulated industries, including relevant threats, vulnerabilities, attack paths, and exploitation techniques.
  • Proficiency in Operational Technology and Industrial Control Systems network design and creating network architecture drawings.
  • Ability to influence others, work effectively, and communicate clearly with operations, engineering, projects, vendors, and peers.
  • Knowledge of techniques and tools that support effective analysis, root cause identification, and issue resolution.
  • Ability to communicate clearly, concisely, and effectively orally and in writing.
  • A Bachelor's degree with 7 years of experience, a Master's degree with 6 years of experience, or a PhD with 2 years of experience in related technical work.
  • In-depth knowledge of the systems development life cycle and technical solution alternatives.
  • Proven implementation of creative technology solutions that advanced the business.
  • Excellent written and oral English communication skills.
Responsibilities
  • Conceive, design, engineer, and implement Operational Technology security solutions by studying operational requirements, collaborating with users and technical teams, reviewing system and network flows, and investigating problem areas.
  • Resolve project challenges and assumptions using available information, technical expertise, and Operational Technology cybersecurity principles.
  • Provide consultation to business unit and IT management and staff on Operational Technology security practices, industrial control environments, network architectures, and supporting technologies across diverse computing environments.
  • Apply pharmaceutical business knowledge to develop agile, impactful, and cost-effective solutions that support secure, reliable, and resilient Operational Technology environments.
  • Work autonomously while maintaining awareness of cybersecurity, system reliability, operational continuity, and risk considerations.
  • Research and evaluate alternative solutions and recommend efficient and cost-effective Operational Technology security solutions.
  • Configure, adapt, or integrate existing technologies and purchased solutions to support secure operations, monitoring, and risk reduction.
  • Build and maintain relationships with affiliates, subsidiaries, vendors, and industry peers in alignment with company values, vendor management, and purchasing requirements.
  • Mentor and/or supervise team members as needed and support performance management, including adherence to security and operational standards.
  • Adhere to corporate and divisional policies, code of conduct, safety, GxP compliance, data security, and secure development and operational practices.
  • Support Operational Technology security aspects of manufacturing and research technology initiatives through architecture, engineering, design, implementation, deployment, and operational transition of secure technology solutions.
  • Lead Operational Technology cybersecurity and secure-by-design assessments, including detailed design reviews, network topology reviews, and mapping data flows to ports, protocols, and services.
  • Contribute to Operational Technology and Industrial Control Systems cybersecurity guardrails to ensure architectures, solutions, and technologies use secure-by-design methodology.
  • Utilize NIST SP 800-53, NIST SP 800-82, and ISA/IEC 62443 to identify security capabilities and technologies that strengthen Operational Technology defenses.
  • Support cybersecurity risk assessments to determine system criticality, exposure, and risk gaps.
  • Provide recommendations and mitigation plans for issues identified through Operational Technology and Industrial Control Systems cybersecurity reviews, risk assessments, and vulnerability assessments.
  • Provide subject matter leadership during cyber incidents, including response, containment, and remediation.
  • Travel up to 20% as required.
Desired Qualifications
  • Familiarity with cloud and Operational Technology/Industrial Control Systems integration.
  • Work experience in the pharmaceutical industry.
  • Experience in regulated environments supporting manufacturing or research operations.

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AbbVie raised 2026 revenue guidance to $67.6 billion after Q2 2026.
  • FDA review of SKYRIZI Crohn's subcutaneous induction targets a late-2026 approval.
  • WCLC 2026 data showed ABBV-1480 90% response in squamous NSCLC.

What critics are saying

  • HUMIRA revenue fell 36.1% in Q2 2026 as biosimilars keep taking share.
  • The Apogee deal cuts 2026 EPS by $0.14 and adds debt financing.
  • Epcoritamab missed the July 23, 2026 DLBCL endpoint, threatening future B-cell franchise growth.

What makes AbbVie unique

  • SKYRIZI and RINVOQ drove $8.8 billion of Q2 2026 immunology revenue.
  • Botox Cosmetic and Juvederm generated $973 million in Q2 2026 aesthetics sales.
  • Apogee purchase adds late-stage IL-13 and TSLP programs for eczema and asthma.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
Yahoo Finance
Aug 21st, 2026
AbbVie stock moves independently from market with 0.22 correlation driven by immunology drugs

AbbVie stock shows a correlation of just 0.22 to the S&P 500 over five years, meaning most of its movements stem from company-specific factors rather than broader market trends. The pharmaceutical firm's immunology segment generated nearly $8.8 billion of its $17 billion in second-quarter 2026 revenue, led by SKYRIZI at $5.5 billion and RINVOQ at over $2.5 billion. These treatments for chronic diseases have prices negotiated with payers, not consumers. AbbVie has delivered an annualised return of 21.5% with 23.5% volatility over five years, compared to the S&P 500's 12.9% return at 17.2% volatility. The company converts 28.3% of revenue into free cash flow, nearly double the S&P 500 median of 14.5%.

Grafa
Aug 21st, 2026
AbbVie reports 90% response in lung cancer study.

AbbVie reports 90% response in lung cancer study. * AbbVie reported a 90% objective response rate for ABBV-1480 plus platinum chemotherapy in squamous advanced NSCLC at the selected 10 mg/kg dose. * The same dose produced a 75.9% response rate in non-squamous disease and was selected as the recommended Phase 3 dose. * AbbVie will also present data for Temab-A and ABBV-706 across NSCLC and small cell lung cancer at the 2026 World Conference on Lung Cancer. AbbVie (NYSE:ABBV) reported Phase 1b lung cancer data showing objective response rates of 90% in squamous and 75.9% in non-squamous advanced NSCLC with ABBV-1480 plus platinum chemotherapy. At the 10 mg/kg dose, 27 of 30 patients with squamous disease and 22 of 29 with non-squamous disease achieved objective responses, according to the company. AbbVie said the findings support further evaluation of ABBV-1480 in advanced NSCLC and selected the 10 mg/kg regimen as the recommended Phase 3 dose. The company will present additional clinical results for telisotuzumab adizutecan, or Temab-A, in first-line non-squamous and EGFR-mutated NSCLC at the 2026 World Conference on Lung Cancer. AbbVie will also report ABBV-706 data in relapsed or refractory small cell lung cancer, including new safety analyses covering 240 patients. The company's conference presentations include real-world evidence evaluating SEZ6 as a potential therapeutic target in small cell lung cancer. The updates form part of AbbVie's clinical development program across non-small cell and small cell lung cancers, with several investigational therapies being evaluated across different treatment settings. Frequently asked questions. ABBV signals

Yahoo Finance
Aug 19th, 2026
AbbVie stock eyes breakout as Skyrizi dosing decision could unlock $24.5B revenue growth

AbbVie stock has returned 24.5% over the past three months, trading near its 52-week high. The pharmaceutical company's growth hinges on a pending regulatory decision for SKYRIZI, an immunology treatment that generates nearly a third of guided revenue. SKYRIZI sold $5.5 billion in Q2 2026, up 24% operationally. AbbVie guides the drug to $21.7 billion for 2026 against total company revenue of approximately $67.6 billion. The company has raised its 2026 guidance twice by $600 million combined. A subcutaneous induction option for Crohn's disease awaits regulatory approval this fall. Management expects the new dosing method to meaningfully accelerate SKYRIZI sales, though the commercial impact won't materialise until early 2027 due to contract timelines. Clinical trial results showed endoscopic response and remission rates 25 points above placebo.

BBC
Aug 19th, 2026
UK's Smith+Nephew CFO John Rogers to step down for external role.

UK's Smith+Nephew CFO John Rogers to step down for external role. August 19, 2026 The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing International News via Reuters: Smith+Nephew said on Wednesday its finance chief John Rogers would step down at the end of September to take up an external position in the United States, ending his roughly two-and-a-half-year tenure with the medical products company. Here are some more details: - The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing. - Smith+Nephew said it had appointed Senior Vice President Finance and Group Controller Pierre Palassian as interim chief financial officer until a permanent replacement was appointed. - Palassian, who joined Smith+Nephew in 2017, previously held senior roles at AbbVie and Abbott Laboratories. - Rogers, who took up the CFO role in early 2024, had relocated to the United States in 2025 for operational efficiencies. - Shares in the FTSE 100 company have gained nearly 14% during Rogers' tenure as CFO. - Smith+Nephew said Rogers would receive no severance payment, and that his outstanding incentive and share awards would lapse on September 30 under leaver rules. Reporting by Neeshita Beura in Bengaluru; Editing by Subhranshu Sahu - Advertisement - August 19, 2026 - Advertisement -

Yahoo Finance
Aug 15th, 2026
AbbVie shows strong cash flow margin of 34.8% but faces tepid revenue growth

AbbVie, the biopharmaceutical company spun off from Abbott Laboratories in 2013, has risen 9.7% to $249.64 per share over the past six months. The company generates $64.39 billion in revenue over the past 12 months, benefiting from significant economies of scale in its operations. AbbVie's free cash flow margin averaged 34.8% over the last five years, amongst the best in the healthcare sector. This strong cash generation enables reinvestment and capital returns to investors. However, the company's five-year annualised revenue growth of 3.7% remains tepid compared to sector peers. Despite this weakness, AbbVie's shares trade at 16.3 times forward price-to-earnings ratio. The company develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions.